Recent Developments in the Treatment of Renal Cell Carcinoma

May 31, 2007
Recent Developments in the Treatment of Renal Cell Carcinoma

Commentary by Michael Seidman MD, Chief Oncology Fellow

New treatment options for both early and advanced Renal Cell Cancer have recently been published. Traditionally, treatment for early stage disease was partial or radical nephrectomy. In the metastatic setting, treatment options were limited to toxic cytokine therapy with IFN or IL-2.

Some recent literature has suggested that small, incidentally found renal tumors can safely be watched without the need for invasive surgery. Remzi et al retrospectively reviewed 287 tumor bearing kidneys 4cm or…

Read more »

New Guidelines on the Management of Intracerebral Hemorrhage

May 30, 2007
New Guidelines on the Management of Intracerebral Hemorrhage

Commentary by Dr. Daniel Labovitz, Director of the NYU Stroke Center

After an 8-year hiatus, the American Heart Association/American Stroke Association has at last published a fresh set of guidelines on the management of acute spontaneous intracerebral hemorrhage (ICH) . ICH represents between 10 and 20% of all first strokes, depending on the population, but carries a mortality rate of 35% to 50%, with hemorrhage volume, hemorrhage location, intraventricular extension and age all contributing independently to the risk of death.…

Read more »

ShortCuts-This week in the Journals

May 29, 2007
ShortCuts-This week in the Journals

The big bomb this past week was the Rosiglitazone Effect. Resulting in front page news in various newspapers (on multiple days), the meta-analysis in last week’s NEJM is causing quite the stir. For more information, see the post.

What’s old is what’s new. An interesting editorial on Medpage reviewed the reason that HCTZ is the most commonly prescribed thiazide, and it’s not efficacy. HCTZ is 4 letters and takes a second to write on a pad, chlorthalidone is 14 letters and, while possibly the…

Read more »

How should you approach a pregnant patient with chronic kidney disease?

May 25, 2007
How should you approach a pregnant patient with chronic kidney disease?

A 31 year old female with hypertension and proteinuria secondary to IgA nephropathy, currently treated with an ARB, presents to clinic stating that she would like to become pregnant.

What is the risk of fetal morbidity in the setting of ARBs/ACE-inhibitors? What antihypertensive medications are used during pregnancy? At what point would you switch a patient’s medications if she is trying to become pregnant? What is the natural course of IgA nephropathy during pregnancy?

-Minisha Sood MD, PGY-3

Pregnancy and Chronic Kidney

Read more »

FDA Black Box Warning on Gadolinium

May 24, 2007

Back in December we reported on the FDA cautioning practioners about the use of gadolinium (an mri contrast agent) in patients with chronic kidney disease.  The FDA is now requesting a black box warning  stating “that patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating, and a potentially fatal disease known as nephrogenic systemic fibrosis (NSF). In addition, it would state that patients just before or just after liver transplantation, or those with chronic liver disease, are also at risk…

Read more »

Not So Rosi…

May 24, 2007
Not So Rosi…

Commentary by Seagram Villagomez MD, Chief Resident

Since its approval in 1999, nearly 1 million Americans have used the thiazolidinedione (TZD) rosiglitazone (Avandia – GlaxoSmithKline) for the treatment of Type 2 Diabetes.  However, in a drug class which seems plagued by concerns, the safety profile associated with rosiglitazone has been brought to question. Previously, troglitazone (Rezulin) was pulled off the market secondary to hepatoxicity, while muraglitazar was not approved by the FDA given adverse cardiovascular events during early clinical trials.  In a…

Read more »

ShortCuts-This Week in the Journals

May 21, 2007
ShortCuts-This Week in the Journals

This week’s review is a potpourri of interesting if not groundbreaking articles.

The pharmaceutical industry certainly got off easier this week (see last week’s shortcuts) and the New York Times focused instead on the “industrialization” of the art of medicine. A hospital group in central Pennsylvania is offering insurers and patients bypass surgery for a flat fee with a 90 day guarantee. They’ve put 40 measures in place to make sure patients receive evidenced based care. If the any of the 40 measure…

Read more »

Clinical Pathology Conference 5/11/07-The Answer

May 18, 2007

Please review the posting of last week’s  CPC Case here.

When you’re ready you can download the CPC Answer here.

Read more »